Publications
Detailed Information
Loss of ataxia-telangiectasia mutated protein expression correlates with poor prognosis but benefits from anthracycline-containing adjuvant chemotherapy in breast cancer : 유방암 환자에서 ataxia-telangiectasia mutated 단백의 소실과 예후 및 안트라싸이클린 계열 보조항암화학치료의 효과의 연관성에 관한 연구
DC Field | Value | Language |
---|---|---|
dc.contributor.advisor | 임석아 | - |
dc.contributor.author | 서경진 | - |
dc.date.accessioned | 2017-07-19T10:35:03Z | - |
dc.date.available | 2017-07-19T10:35:03Z | - |
dc.date.issued | 2016-08 | - |
dc.identifier.other | 000000136866 | - |
dc.identifier.uri | https://hdl.handle.net/10371/132891 | - |
dc.description | 학위논문 (석사)-- 서울대학교 대학원 : 의학과 분자종양의학, 2016. 8. 임석아. | - |
dc.description.abstract | Purpose: We investigated the correlation of ataxia-telangiectasia mutated (ATM) protein expression with clinicopathological features and prognosis in patients with breast cancer.
Methods: ATM expression was determined by immunohistochemistry in 420 surgically resected breast tumors. Results: ATM loss was observed in 126/407 evaluable cases (31.0%), and was significantly associated with larger tumor size, lymph node metastasis, higher tumor grade, and ER- and/or PR-negative status. ATM loss was also associated with significantly lower disease-free survival rates than those in patients with intact ATM (5-year disease-free survival rate 81.2% vs. 90.7%, p = 0.015). In multivariate analysis, ATM loss combined with abnormal p53 expression was an independent predictor of shorter disease-free survival (hazard ratio [HR] 3.48 | - |
dc.description.abstract | 95% confidence interval [CI], 1.48 - 8.17, p = 0.004). A tendency towards a poorer prognosis was observed for tumoral ATM loss alone, although statistical significance was not reached (HR 1.74 | - |
dc.description.abstract | 95% CI 0.95 - 3.20 | - |
dc.description.abstract | p = 0.075). In subgroup analysis, ATM loss was associated with shorter disease-free survival in patients who did not receive adjuvant anthracycline chemotherapy (5-year disease-free survival rate 92.7% in intact ATM group vs. 68.1% in ATM loss group, p = 0.002), but this poor prognosis was overcome in patients who did (5-year disease-free survival rate 89.8% vs. 84.4%, p = 0.243), suggesting more benefit from anthracycline-based chemotherapy.
Conclusion: Tumors with loss of ATM expression have a poor prognosis and their prognoses are dependent on the use of adjuvant anthracycline. ATM loss might be a practical tool for predicting benefits from anthracycline-based adjuvant therapy. | - |
dc.description.tableofcontents | Introduction 1
Methods 3 Results 6 Discussion 28 References 34 국문 초록 40 | - |
dc.format | application/pdf | - |
dc.format.extent | 1915743 bytes | - |
dc.format.medium | application/pdf | - |
dc.language.iso | en | - |
dc.publisher | 서울대학교 대학원 | - |
dc.subject | ataxia-telangiectasia mutated (ATM) | - |
dc.subject | p53 | - |
dc.subject | immunohistochemistry | - |
dc.subject | prognosis | - |
dc.subject | anthracycline | - |
dc.subject | PARP-1 inhibitor | - |
dc.subject.ddc | 610 | - |
dc.title | Loss of ataxia-telangiectasia mutated protein expression correlates with poor prognosis but benefits from anthracycline-containing adjuvant chemotherapy in breast cancer | - |
dc.title.alternative | 유방암 환자에서 ataxia-telangiectasia mutated 단백의 소실과 예후 및 안트라싸이클린 계열 보조항암화학치료의 효과의 연관성에 관한 연구 | - |
dc.type | Thesis | - |
dc.description.degree | Master | - |
dc.citation.pages | 41 | - |
dc.contributor.affiliation | 의과대학 의학과 | - |
dc.date.awarded | 2016-08 | - |
- Appears in Collections:
- Files in This Item:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.